Identification, genetic testing, and management of hereditary melanoma. External Web Site Icon Leachman Sancy A et al. Cancer metastasis reviews 2017 Mar 36(1) 77-90

https://phgkb.cdc.gov/GAPPKB/phgHome.do




Last Posted: May 11, 2017

---

• Identification, genetic testing, and management of hereditary melanoma.  
  Leachman Sancy A et al. Cancer metastasis reviews 2017 Mar 36(1) 77-90
• Whole-genome landscapes of major melanoma subtypes  
  NK Hayward et al, Nature, May 3, 2017
• StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.  
  Sen Manimala et al. Cancer medicine 2017 Apr
• Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.  
  de Unamuno Bustos Blanca et al. Scientific reports 2017 Mar 7(1) 495
• Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.  
   et al. JAMA oncology 2017 Feb
• Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.  
  Zheng Gang et al. American journal of clinical pathology 2016 May 145(5) 696-702
• Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.  
  Kohn Christine G et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Feb JCO2016696336
• Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.  
  Hamblin Angela et al. PLoS medicine 2017 Feb 14(2) e1002230
• Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.  
  Paasinen-Sohns Aino et al. Neoplasia (New York, N.Y.) 2017 Feb 19(3) 196-206
• Targeted pharmacotherapy after somatic cancer mutation screening.  
  Polasek Thomas M et al. F1000Research 2016 51551
• Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.  
  Borroni Riccardo G et al. Melanoma research 2017 Jan
• Translation and adaptation of skin cancer genomic risk education materials for implementation in primary care.  
  Rodríguez Vivian M et al. Journal of community genetics 2016 Dec
• Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.  
  van Amerongen Rosa A et al. Ecancermedicalscience 2016 10684
• Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.  
  Levin Trine et al. Familial cancer 2016 Nov
• Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study.  
  Liang R et al. European journal of cancer care 2016 Oct
• A pilot randomised controlled trial of the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public.  
  Smit Amelia K et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016 Oct

more